- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/116 - Polyvalent bacterial antigens
Patent holdings for IPC class A61K 39/116
Total number of patents in this class: 277
10-year publication summary
|
26
|
4
|
25
|
11
|
23
|
17
|
14
|
11
|
22
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1639 |
39 |
| Pfizer Inc. | 3379 |
8 |
| Merck Sharp & Dohme LLC | 3749 |
7 |
| Novartis AG | 10867 |
6 |
| Cansino Biologics Inc. | 74 |
6 |
| Wyeth LLC | 652 |
5 |
| Wyeth Holdings LLC | 54 |
4 |
| University of Tennessee Research Foundation | 758 |
4 |
| Previwo AS | 21 |
4 |
| SK Bioscience Co., Ltd. | 114 |
4 |
| Vaxxinova US, Inc. | 50 |
4 |
| The Regents of the University of Michigan | 4685 |
3 |
| Baxalta GmbH | 104 |
3 |
| Baxalta Incorporated | 302 |
3 |
| Keio University | 1093 |
3 |
| Longhorn Vaccines and Diagnostics, LLC | 87 |
3 |
| Ohio State Innovation Foundation | 2120 |
3 |
| Sanofi Pasteur Inc. | 358 |
3 |
| Serum Institute of India Private Limited | 99 |
3 |
| University of Maryland, Baltimore | 1015 |
3 |
| Other owners | 159 |